1 / 14

Breast Cancer Treatment Options for a 74-Year-Old Woman

This case study follows a 74-year-old woman with a lump in her left breast. The patient's medical history, examination results, and recommended treatment options are discussed. The study also explores the Nottingham Prognostic Index, reasons for mastectomy, and post-operative therapies.

renna
Télécharger la présentation

Breast Cancer Treatment Options for a 74-Year-Old Woman

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Case 3 • Jane McNicholas • Consultant Oncoplastic Breast Surgeon • East Lancashire Hospitals

  2. Case 3 • 74 year old woman presents with lump in left breast she noticed 2 weeks ago • In past, was on HRT for 7 years • No FH of breast cancer • Otherwise fit and well

  3. Case 3 • On examination - 2cm mass in left breast, hard, discrete, feels malignant. No axillary nodes to feel - P5 • Mammogram - 2cm mass in left breast - M5 • Ultrasound - 22mm lesion in breast - U5 • Ultrasound of axilla - normal • FNA - malignant cells - M5 • Core Biopsy - Invasive Ductal Cancer, Grade 2 - B5b

  4. Case 3 • What do you offer the patient?

  5. Case 3 • WLE + SLNB • Mastectomy + SLNB • Axillary node clearance only if SLNB shows metastatic disease • Post-op radiotherapy? • Post-op chemotherapy? • Endocrine therapy?

  6. Case 3 • Patient chooses WLE and SLNB • Post op histology - 19mm Grade 2 Invasive Ductal Cancer, fully excised. No evidence of lymphovascular invasion. 0/4 lymph nodes • ER - 8/8, PR - 7/8, Her2 - -ve • What is her NPI?

  7. Nottingham Prognostic Index • NPI = Grade + Lymph Nodes + (Size (cm) x0.2)

  8. Nottingham Prognostic Index

  9. Case 3 • NPI = 2 + 1 + (1.9 x 0.2) = 3.38 • Puts patient into a good prognosis group • Post-operative MDT recommended radiotherapy and endocrine therapy (Aromatase inhibitor)

  10. Reasons for Mastectomy • Patient choice • Large tumour in relation to breast size • Previous breast conserving surgery with radiotherapy • Multi-focal disease • Unable to have radiotherapy (unable to lie flat, unable to raise arm, pacemaker with left sided tumour • Patients with collagen vascular diseases • Central breast tumour - No longer a valid reason

  11. Post-op Radiotherapy • Always given after WLE - local recurrence rate unacceptably high if not given (i.e 25% in 10 years) • Given after mastectomy in patients thought to be at higher risk of local recurrence (i.e. close to chest wall, large tumour, vascular invasion, etc

  12. Post-op Chemotherapy • Given to patients at high risk of disease recurrence/progression • Usually node positive, large tumour, adverse histological features, oestrogen receptor negative, herceptin positive • Traditionally given up to 70, but this is changing - over 70 given in many more cases if fit enough

  13. Endocrine Therapy • Given to patients who are Oestrogen Receptor positive • First used was Tamoxifen. Side effects include hot flushes (50%), increased thrombo-embolic risk, increased risk of endometrial cancer • Newer agents more widely used now - Anastrozole (Arimidex), Letrozole (Femara) and Exemestane (Aromasin). Side effects are hot flushes (30%) and reduced bone mineral density

  14. HRT and Breast Cancer • The Million Women Study is the largest study looking at HRT usage and breast cancer risk • It found that taking HRT for 5 years increased the risk of breast cancer • This increased risk was for Oestrogen only and Combined Preparations but Combined preparations had a greater risk

More Related